Select pharma shares on a roll, Wockhardt zooms 20%

Strides Arcolab, Ranbaxy and Aurobindo Pharma have rallied between 6-13% on the Bombay Stock Exchange.

SI Reporter Mumbai
Last Updated : Apr 02 2014 | 1:37 PM IST
Shares of pharmaceutical companies are trading higher by up to 20% on back of heavy volumes on the bourses.

Wockhardt, Strides Arcolab and Ranbaxy Laboratories have rallied between 10-20%, while Aurobindo Pharma, Cadila Healthcare, Cipla, Biocon, Lupin and Divi’s Laboratories are trading higher in the range of 2-6% on the BSE.

The BSE pharmaceutical index S&P BSE Healthcare, the largest gainer among sectoral indices, is up 2.14% compared to 0.35% rise in benchmark S&P BSE Sensex at 1230 hours.

According to a recent Economic Times report, the US Food and Drug Administration (US FDA) has detected no impurity in the Indian version of cholesterol-lowering generic drug Atorvastat in recent tests.

That may be seen “as a positive” for companies as facilities of many top Indian drug firms such as Ranbaxy, Wockhardt, Sun Pharma have been recently red flagged by the US FDA.

Among the individual stocks, Wockhardt, the largest gainer among the pack, is locked in upper circuit of 20% at Rs 552 on the BSE. The company is facing various regulatory issues, including USFDA import alert at Waluj and Chikalthana units.

The stock has seen huge trading activity with a combined 8.2 million shares already changed hands and there are pending buy orders for 602,700 shares on the BSE and NSE.

Strides Arcolab has soared 13% to Rs 434, followed by Ranbaxy Laboratories (11% at Rs 410) and Aurobindo Pharma (6% to Rs 569).
 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 02 2014 | 12:54 PM IST

Next Story